Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.
Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.
Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.
Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.
Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.
Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.
With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.
Arcus Biosciences, Inc. (NYSE: RCUS) has granted five new employees options to purchase a total of 44,200 shares at an exercise price of $34.31, reflecting the closing price on September 8, 2021. This grant is part of the Company's 2020 Inducement Plan, approved by the Board in January 2020, in compliance with NYSE regulations. Arcus focuses on developing innovative cancer therapies, with five molecules currently in clinical development addressing significant unmet medical needs.
Arcus Biosciences (NYSE:RCUS) announced its upcoming presentations at two virtual investor conferences in September 2021. The Citi’s 16th Annual Virtual Biopharma Conference will take place on September 10 at 1:25 pm ET, followed by the 2021 Cantor Virtual Global Healthcare Conference on September 27 at 4:40 pm ET. Investors can access a live audio webcast through the company’s website, with a replay available for two weeks post-event. Arcus focuses on developing innovative cancer therapies, currently advancing five molecules in clinical trials.
Arcus Biosciences (NYSE:RCUS) has granted stock options for 104,200 shares to twelve new employees at an exercise price of $29.35, reflecting the closing price on August 23, 2021. This grant is part of the 2020 Inducement Plan approved in January 2020, under NYSE Manual Rule 303A.08. The company is dedicated to developing innovative cancer therapies and currently has five drugs in clinical development, including Etrumadenant and Quemliclustat, targeting various cancer types.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options for 30,400 shares to four new employees. The options are priced at $28.24 per share, equivalent to the closing price on August 9, 2021. This issuance falls under the Company’s 2020 Inducement Plan, approved in January 2020. Arcus Biosciences focuses on developing innovative cancer therapies, with five molecules currently in clinical development targeting various oncology indications.
Arcus Biosciences (NYSE:RCUS) reported its Q2 2021 financial results, showing significant advancements in its oncology portfolio. The company ended June with cash and investments of $805.1 million, an increase from $735.1 million in December 2020, primarily due to a $220.4 million stock placement with Gilead. Collaboration revenues surged to $9.5 million, compared to $1.8 million a year earlier. However, the net loss rose to $76 million in Q2 2021, up from $45.1 million in Q2 2020, indicating increased operational costs.
Arcus Biosciences, Inc. (NYSE:RCUS), a biopharmaceutical company focused on oncology, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on August 11, 2021, at 1:45 p.m. ET. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for two weeks post-event. Arcus is advancing five clinical molecules, including Etrumadenant (AB928) and AB680, targeting multiple cancers. The company's innovative approaches aim to address significant unmet medical needs in cancer therapy.
Arcus Biosciences (NYSE:RCUS) will report its financial results for Q2 2021 on August 5, 2021, after market close. A conference call to discuss these results and corporate highlights will begin at 1:30 PM PT/4:30 PM ET. Investors can join via phone or listen to a live webcast on the company's website. Arcus is advancing five molecules in clinical development, including Etrumadenant and AB680, targeting various cancers with promising therapies aimed at addressing unmet medical needs.
Arcus Biosciences (NYSE:RCUS) announced the grant of stock options for 72,800 shares to six new employees at an exercise price of $32.85, corresponding to the closing price on July 23, 2021. This grant is made under the Company’s 2020 Inducement Plan, approved by its Board of Directors. Arcus focuses on developing innovative cancer therapies and has five molecules in clinical development, including Etrumadenant and Domvanalimab, targeting significant unmet needs in various cancers. The company aims to advance its portfolio through clinical trials and collaborations.
Arcus Biosciences, Inc. (NYSE:RCUS) announced that its Board's Compensation Committee granted options to purchase 77,800 shares to seven new employees at an exercise price of $28.75, the closing price on July 8, 2021. This grant is part of the 2020 Inducement Plan, approved under NYSE rules. Arcus focuses on developing innovative cancer therapies with five molecules in clinical stages, including Etrumadenant for various cancers and AB680 for metastatic pancreatic cancer.
Arcus Biosciences (NYSE:RCUS) announced the grant of stock options to ten new employees, totaling 141,800 shares at an exercise price of $23.40, based on the closing price from June 23, 2021. This issuance is part of the Company’s 2020 Inducement Plan approved by the Board. Arcus is focused on developing innovative cancer therapies, with five molecules currently in clinical trials, including the promising Etrumadenant and Domvanalimab, aimed at addressing significant unmet needs in oncology.
FAQ
What is the current stock price of Arcus Biosciences (RCUS)?
What is the market cap of Arcus Biosciences (RCUS)?
What does Arcus Biosciences, Inc. do?
Where is Arcus Biosciences located?
When was Arcus Biosciences founded?
What is the core focus of Arcus Biosciences' research?
What are some of Arcus Biosciences' main products?
What types of cancer does Arcus Biosciences target?
Does Arcus Biosciences outsource its research and development?
With whom does Arcus Biosciences have significant partnerships?
What makes Arcus Biosciences unique?
What is the mission of Arcus Biosciences?
